

# Supporting information

## Naturally occurring 8 $\beta$ ,13 $\beta$ -kaur-15-en-17-al and anti-malarial activity from *Podocarpus polystachyus* leaves

Mira Syahfriena Amir Rawa<sup>a,b,c</sup>, Mohammad G. Al-Thiabat<sup>a</sup>, Toshihiko Nogawa<sup>c,d</sup>, Yushi Futamura<sup>e</sup>, Akiko Okano<sup>e</sup>, and Habibah A. Wahab<sup>a,b,c,\*</sup>

<sup>a</sup>School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia

<sup>b</sup>Collaborative Laboratory of Herbal Standardization (CHEST), School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11900 Bayan Lepas, Malaysia

<sup>c</sup>USM-RIKEN Interdisciplinary Collaboration for Advanced Science (URICAS), Universiti Sains Malaysia, 11800 Minden, Penang Malaysia

<sup>d</sup>Molecular Structure Characterization Unit, Technology Platform Division, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Saitama 351-0198, Japan

<sup>e</sup>Chemical Biology Research Group, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan

### Correspondence

Prof. Habibah A. Wahab

School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia

Tel: +604-6577888

Email: habibahw@usm.my

Orcid ID: 0000-0002-8353-8679

## Contents:

- Figure S1.** Isolation scheme of the leaves extract from *Podocarpus polystachyus*. / page 4
- Figure S2.** HR-ESI-TOF-MS spectrum of **1**. / page 5
- Figure S3.** HR-ESI-TOF-MS spectrum of **2**. / page 6
- Figure S4.** HR-ESI-TOF-MS spectrum of **3**. / page 7
- Figure S5.** HR-EI-TOF-MS spectrum of **4**. / page 8
- Figure S6.**  $^1\text{H}$  NMR spectrum of **1**. / page 9
- Figure S7.**  $^{13}\text{C}$  NMR spectrum of **1**. / page 10
- Figure S8.** DEPT-135 spectrum of **1**. / page 11
- Figure S9.** HSQC spectrum of **1**. / page 12
- Figure S10.** DQF-COSY spectrum of **1**. / page 13
- Figure S11.** HMBC spectrum of **1**. / page 14
- Figure S12.** NOESY spectrum of **1**. / page 15
- Figure S13.** Conformation analysis and calculation of NMR chemical shifts of  $8\beta,13\beta$ -kaur-15-en-17-al. / page 16
- Figure S14.** Conformation analysis and calculation of ECD spectra of enantiomer of  $8\beta,13\beta$ -kaur-15-en-17-al. / page 17
- Figure S15.** Experimental and calculated ECD spectra of **1**. / page 18
- Figure S16.**  $^1\text{H}$  NMR spectrum of **2**. / page 19
- Figure S17.**  $^{13}\text{C}$  NMR spectrum of **2**. / page 20
- Figure S18.** DEPT-90 and DEPT-135 experiments of **2**. / page 21
- Figure S19.** HSQC spectrum of **2**. / page 22
- Figure S20.** DQF-COSY spectrum of **2**. / page 23
- Figure S21.** HMBC spectrum of **2**. / page 24
- Figure S22.**  $^1\text{H}$  NMR spectrum of **3**. / page 25
- Figure S23.**  $^{13}\text{C}$  NMR spectrum of **3**. / page 26
- Figure S24.** DEPT-135 spectrum of **3**. / page 27
- Figure S25.** HSQC spectrum of **3**. / page 28
- Figure S26.** DQF-COSY spectrum of **3**. / page 29
- Figure S27.** HMBC spectrum of **3**. / page 30
- Figure S28.** NOESY spectrum of **3**. / page 31
- Figure S29.**  $^1\text{H}$  NMR spectrum of **4**. / page 32
- Figure S30.**  $^{13}\text{C}$  NMR spectrum of **4**. / page 33

**Figure S31.** DEPT-135 spectrum of **4**. / page 34

**Figure S32.** HSQC-TOCSY spectrum of **4**. / page 35

**Figure S33.** DQF-COSY spectrum of **4**. / page 36

**Figure S34.** HMBC spectrum of **4**. / page 37

**Figure S35.** NOESY spectrum of **4**. / page 38


**Figure S36.** Superimposition of the crystal structure of 3,5-dihydroxy-2-naphthoic acid (C pink and O red) and the docked model (C green and O red) on Plasmodium falciparum lactate dehydrogenase crystal structure (PDB ID: 1U5A) with RMSD ~ 2.0 Å and their 2D interactions into the binding site. / page 39

**Figure S37.** Hydrogen bond profiles obtained from MD simulations (0–100 ns) for all systems: (a) *PfLDH*-apo, (b) *PfLDH*- control, (c) *PfLDH-1*, and (d) *PfLDH-2*. / page 40

**Figure S38.** Specimen ID and sample report of *P. polystachyus*. / page 41

**Table S1.** Infection rates of compounds **1** and **2** in comparison to artemisinin as the reference drug. / page 42

**Table S2.** IC<sub>50</sub> of compounds **1** and **2** in comparison to artemisinin as the reference drug. / page 42




**Figure S1.** Isolation scheme of the leaf extract from *Podocarpus polystachyus*.

## Compound 1

Item name: 210908\_USM0019\_Hex\_F0011p Channel name: 2: Average Time 4.7322 min : HD TOF MSe (50-1500) 4eV ESI+ : Centroided : Combi...

Item description:

8.22e4



*m/z*: 287.23654 [M+H]<sup>+</sup>

Composition	i-FIT Confidence (%)	m/z RMS (PPM)	Intensity RMS (%)	Predicted m/z	m/z error (PPM)	m/z error (mDa)	DBE
C20H30O	100.000000	1.468589	12.995479	287.236942	-1.404578	-0.402031	6.000000

*m/z*: 269.22581 [M+H-H<sub>2</sub>O]<sup>+</sup>


Composition	i-FIT Confidence (%)	m/z RMS (PPM)	Intensity RMS (%)	Predicted m/z	m/z error (PPM)	m/z error (mDa)	DBE
C20H28	100.000000	2.721461	7.787655	269.226377	-2.115235	-0.567345	7.000000

**Figure S2.** HR-ESI-TOF-MS spectrum of **1**.

## Compound 2

Item name: 210908\_USM0019\_Hex\_F0035 Channel name: 2: Average Time 4.5518 min : HD TOF MSe (50-1500) 4eV ESI+ : Centroided : Combin...

Item description:



$m/z: 271.24172 [M+H-H_2O]^+$

Composition	i-FIT Confidence (%)	m/z RMS (PPM)	Intensity RMS (%)	Predicted m/z	m/z error (PPM)	m/z error (mDa)	DBE
C20H30	100.000000	1.490177	3.043532	271.242027	-1.137564	-0.307409	6.000000

$m/z: 559.48765 [2M+H-H_2O]^+$

Composition	i-FIT Confidence (%)	m/z RMS (PPM)	Intensity RMS (%)	Predicted m/z	m/z error (PPM)	m/z error (mDa)	DBE
C40H62O	100.000000	0.581055	1.098484	559.487343	0.549613	0.306948	10.000000

$m/z: 541.47723 [2M+H-2H_2O]^+$

Composition	i-FIT Confidence (%)	m/z RMS (PPM)	Intensity RMS (%)	Predicted m/z	m/z error (PPM)	m/z error (mDa)	DBE
C40H60	100.000000	1.078207	9.476290	541.476778	0.835632	0.451634	11.000000

**Figure S3.** HR-ESI-TOF-MS spectrum of 2.


## Compound 3

Data:20210909\_003-Profile  
 Comment:USM0019-EtOAc-F0009\_0.1mg/mL+PFTBA,sless1uL(70–325i250,14min)  
 Description:  
 Ionization Mode: EI+(eiFi)  
 History:Centroid[Peak Detect[Centroid,30,Area];Smooth[3]];Average(MS[1] 11.10..11.24)

Acquired:2021/09/09 16:02:16  
 Operator:AccuTOF  
 m/z Calibration File:PFTBA800\_EI\_pos  
 Created:2021/09/09 16:36:17  
 Created by:AccuTOF

Charge number:1 Tolerance:1.00[ppm], 5.00 .. [mDa] Unsaturation Number:−8.0 .. 80.0 (Fraction:...

Element:<sup>12</sup>C:3 .. 20, <sup>1</sup>H:2 .. 32




Mass	Intensity	Calc. Mass	Mass Difference [mDa]	Mass Difference [ppm]	Possible Formula	Unsaturation Number
41.03917	21306.96	41.03913	0.05	1.18	<sup>12</sup> C <sub>3</sub> <sup>1</sup> H <sub>6</sub>	1.5
55.05484	18356.58	55.05478	0.06	1.14	<sup>12</sup> C <sub>4</sub> <sup>1</sup> H <sub>7</sub>	1.5
79.05493	17847.33	79.05478	0.15	1.91	<sup>12</sup> C <sub>6</sub> <sup>1</sup> H <sub>7</sub>	3.5
81.07039	18665.05	81.07043	-0.03	-0.41	<sup>12</sup> C <sub>5</sub> <sup>1</sup> H <sub>9</sub>	2.5
91.05498	24823.68	91.05478	0.20	2.23	<sup>12</sup> C <sub>7</sub> <sup>1</sup> H <sub>7</sub>	4.5
93.07038	14401.98	93.07043	-0.04	-0.47	<sup>12</sup> C <sub>5</sub> <sup>1</sup> H <sub>9</sub>	3.5
95.08604	14167.45	95.08608	-0.04	-0.40	<sup>12</sup> C <sub>7</sub> <sup>1</sup> H <sub>11</sub>	2.5
105.07053	16966.44	105.07043	0.11	1.01	<sup>12</sup> C <sub>8</sub> <sup>1</sup> H <sub>9</sub>	4.5
109.10151	12509.90	109.10173	-0.21	-1.93	<sup>12</sup> C <sub>8</sub> <sup>1</sup> H <sub>13</sub>	2.5
119.08613	11896.73	119.08608	0.06	0.49	<sup>12</sup> C <sub>9</sub> <sup>1</sup> H <sub>11</sub>	4.5
123.11731	15913.46	123.11738	-0.06	-0.49	<sup>12</sup> C <sub>9</sub> <sup>1</sup> H <sub>15</sub>	2.5
133.10180	9297.61	133.10173	0.07	0.55	<sup>12</sup> C <sub>10</sub> <sup>1</sup> H <sub>13</sub>	4.5
137.13291	7333.20	137.13303	-0.12	-0.86	<sup>12</sup> C <sub>10</sub> <sup>1</sup> H <sub>17</sub>	2.5
147.11736	8160.18	147.11738	-0.02	-0.11	<sup>12</sup> C <sub>11</sub> <sup>1</sup> H <sub>15</sub>	4.5
159.11755	6419.89	159.11738	0.17	1.07	<sup>12</sup> C <sub>12</sub> <sup>1</sup> H <sub>15</sub>	5.5
175.14874	5522.66	175.14868	0.06	0.35	<sup>12</sup> C <sub>13</sub> <sup>1</sup> H <sub>19</sub>	4.5
187.14886	7151.34	187.14868	0.18	0.97	<sup>12</sup> C <sub>14</sub> <sup>1</sup> H <sub>19</sub>	5.5
201.16448	3169.76	201.16433	0.16	0.78	<sup>12</sup> C <sub>15</sub> <sup>1</sup> H <sub>21</sub>	5.5
215.18013	2149.29	215.17998	0.16	0.74	<sup>12</sup> C <sub>16</sub> <sup>1</sup> H <sub>23</sub>	5.5
229.19552	20388.62	229.19563	-0.10	-0.45	<sup>12</sup> C <sub>17</sub> <sup>1</sup> H <sub>25</sub>	5.5
243.21121	1500.19	243.21128	-0.07	-0.28	<sup>12</sup> C <sub>18</sub> <sup>1</sup> H <sub>27</sub>	5.5
244.21835	1645.92	244.21910	-0.75	-3.08	<sup>12</sup> C <sub>18</sub> <sup>1</sup> H <sub>28</sub>	5.0
257.22694	16372.79	257.22693	0.01	0.05	<sup>12</sup> C <sub>19</sub> <sup>1</sup> H <sub>29</sub>	5.5
272.25027	21381.51	272.25040	-0.13	-0.46	<sup>12</sup> C <sub>20</sub> <sup>1</sup> H <sub>32</sub>	5.0

Figure S4. HR-ESI-TOF-MS spectrum of 3.

## Compound 4

Item name: USM0019H-F0016\_p\_CV30 Channel name: 2: Average Time 6.0073 min : HD TOF MSe (50-1500) 4eV ESI+ : Centroided : Combined  
Item description:




*m/z*: 447.38318 [M+H]<sup>+</sup>

Composition	i-FIT Confidence (%)	m/z RMS (PP M)	Intensity RMS (%)	Predicted m/z	m/z error (PP M)	m/z error (m Da)	DBE
C29H50O3	100.000000	0.891141	3.402658	447.383272	-0.205911	-0.091914	5.000000


*m/z*: 429.37266 [M+H-H<sub>2</sub>O]<sup>+</sup>

Composition	i-FIT Confidence (%)	m/z RMS (PP M)	Intensity RMS (%)	Predicted m/z	m/z error (PP M)	m/z error (m Da)	DBE
C29H48O2	100.000000	2.798494	39.760358	429.372707	-0.110251	-0.047228	6.000000


**Figure S5.** HR-EI-TOF-MS spectrum of 4.




**Figure S6.**  $^1\text{H}$  NMR spectrum of **1**.




**Figure S7.**  $^{13}\text{C}$  NMR spectrum of **1**.




**Figure S8.** DEPT-135 spectrum of 1.




**Figure S9.** HSQC spectrum of **1**.



**Figure S10.** DQF-COSY spectrum of **1**.




**Figure S11.** HMBC spectrum of **1**.




**Figure S12.** NOESY spectrum of **1**.

	Starting structure			Optimized structure		
H	1.372017	-3.184947	-1.265359	H	1.390576	-3.135287
C	0.281771	-3.098313	-1.302125	C	0.295343	-3.074964
C	0.155735	-0.81795	-0.097608	C	0.174174	-0.78784
C	0.222443	-0.976649	-2.770696	C	0.217692	-0.977299
C	-0.234505	-0.189151	-1.490133	C	-0.219436	-0.186269
C	-0.155737	-2.471308	-2.618847	C	-0.181133	-2.45647
C	-0.245482	-2.318605	-0.099631	C	-0.21972	-2.281923
H	-0.101713	4.124839	-1.253201	H	-0.061565	-4.10916
H	-1.246863	-2.577635	-2.6946	H	-1.278761	-2.523228
H	0.26266	-3.05479	-3.449052	H	0.190957	-3.036934
H	-1.340217	-2.405264	-0.090327	H	-1.317391	-2.356018
H	0.110325	-2.810446	0.813937	H	0.141829	-2.743046
C	0.078433	1.322462	-1.524055	C	0.100088	1.31443
C	-0.708749	2.076734	-0.452013	C	-0.715444	2.070874
C	-0.543803	1.502135	0.956293	C	-0.56943	1.526399
C	-0.69623	-0.057284	1.002438	C	-0.691173	-0.035611
H	-0.199067	1.754207	-2.490646	H	-0.130435	1.722651
H	1.149045	1.51324	-1.405313	H	1.170497	1.493925
H	-1.771534	2.046818	-0.728899	H	-1.776831	2.002412
H	-0.419857	3.135438	-0.475945	H	-0.463052	3.13902
C	-0.549326	-0.614045	2.453017	C	-0.516341	-0.569134
C	-1.19362	0.275936	3.538377	C	-1.220823	0.266416
C	-1.011256	1.779172	3.276179	C	-1.054646	1.777321
C	-1.607394	2.103054	1.90587	C	-1.651303	2.09482
H	0.505694	-0.733161	2.716574	H	0.547904	-0.607488
H	-0.990224	-1.615597	2.517339	H	-0.879847	-1.59987
H	-0.774505	0.008572	4.51603	H	-0.82195	-0.006954
H	-2.26684	0.051487	3.585176	H	-2.293793	0.038445
H	-1.463037	2.391848	4.061496	H	-1.480811	2.35342
H	-2.605041	1.671781	1.762252	H	-2.63428	1.639321
H	-1.701007	3.190667	1.770175	H	-1.741901	3.177478
C	-0.550242	-0.451207	-4.011211	C	-0.562741	-0.443207
H	-0.238844	0.559861	-4.291653	H	-0.21409	0.54426
H	-1.631042	-0.434626	-3.83162	H	-1.635896	-0.371434
H	-0.374002	-1.091704	-4.88386	H	-0.436643	-1.119857
H	-1.335353	-0.253197	-1.526275	H	-1.320465	-0.257751
H	-1.749624	-0.252218	0.741336	H	-1.735197	-0.235304
C	1.718442	-0.834374	-3.107112	C	1.713728	-0.858674
H	2.025824	0.214938	-3.154151	H	2.028504	0.189748
H	2.370125	-1.347555	-2.401911	H	2.358557	-1.371207
H	1.936034	-1.273615	-4.088769	H	1.908324	-1.301349
C	1.670106	-0.729378	0.210763	C	1.680648	-0.67687
H	2.265403	-1.40764	-0.399266	H	2.264219	-1.378
H	2.082247	0.268025	0.057396	H	2.084662	0.318308
H	1.896029	-1.020158	1.239826	H	1.887802	-0.915972
C	0.696972	1.98901	1.684244	C	0.673227	1.975271
H	1.655726	2.168223	1.219332	H	1.651949	2.113848
C	0.421627	2.126964	2.99061	C	0.401092	2.11454
C	1.374296	2.556587	4.020398	C	1.388305	2.432619
H	2.392694	2.784875	3.665138	H	2.407227	2.669991
O	1.061464	2.653623	5.20008	O	1.147789	2.441601
						5.209086




**Figure S13.** Conformation analysis and calculation of NMR chemical shifts of 8β,13β-kaur-15-en-17-al.


Starting structure			Optimized structure		
H	-2.080519	1.232101	-1.320229	H	-2.020478
C	-2.022778	0.148036	-1.15437	C	-1.978365
C	-0.941188	0.363031	1.137383	C	-0.937473
C	-3.476718	0.285775	0.905948	C	-3.443419
C	-2.288475	-0.008343	1.855503	C	-2.279827
C	-3.323148	-0.300162	-0.490978	C	-3.287212
C	-0.748853	-0.183013	-0.329466	C	-0.724377
H	-1.965101	-0.313056	-2.14794	H	-1.889221
H	-4.413484	-0.079804	1.345912	H	-4.388298
H	-3.595903	1.373255	0.802116	H	-3.509093
H	-4.16705	0.030067	-1.109029	H	4.129286
H	-3.388624	-1.391917	-0.455241	H	-3.336498
C	0.484803	0.596805	-0.949573	C	0.486322
C	1.785959	0.520358	-0.078768	C	1.79157
C	1.536929	0.841315	1.396245	C	1.509201
C	0.324078	0.123624	1.989345	C	0.309889
H	2.422299	0.604314	2.000263	H	2.413099
H	1.376841	1.922759	1.505456	H	1.313696
H	0.53791	-0.943607	2.098896	H	0.534804
H	0.186622	0.509021	3.004373	H	0.139529
C	2.806807	1.517379	-0.676968	C	2.786333
C	3.244844	0.782463	-1.944269	C	3.233046
C	2.10527	0.871178	-2.971509	C	2.081245
C	0.771398	0.290677	-2.452867	C	0.789067
H	3.661961	1.672525	-0.002638	H	3.627884
H	2.374528	2.503415	-0.883828	H	2.32284
H	4.183215	1.186742	-2.334419	H	4.162162
H	1.949756	1.924099	-3.238981	H	1.910699
H	2.386973	0.351368	-3.895299	H	2.360408
H	0.797749	-0.788578	-2.629594	H	0.870378
H	-0.042584	0.677717	-3.076781	H	-0.054529
C	-2.359283	-1.458618	2.368457	C	-2.366477
H	-2.432202	-2.195621	1.570419	H	-2.432077
H	-3.250816	-1.603848	2.991359	H	-3.261486
H	-1.494229	-1.712292	2.989007	H	-1.499646
C	-0.526902	-1.713879	-0.38815	C	-0.486359
H	-1.430478	-2.280164	-0.165831	H	-1.402467
H	0.237074	-2.064236	0.305957	H	0.25581
H	-0.236163	-2.04737	-1.387559	H	-0.146368
C	2.569974	-0.75924	-0.312081	C	2.554279
H	2.468566	-1.661537	0.27362	H	2.423131
C	3.37626	-0.600415	-1.373268	C	3.363903
C	-2.485041	0.899281	3.100328	C	-2.453816
H	-1.775153	0.661549	3.898712	H	-1.779747
H	-2.365639	1.958366	2.845885	H	-2.27509
H	-3.490156	0.775913	3.521442	H	-3.476741
H	-1.003493	1.458424	1.021172	H	-1.000396
H	0.192493	1.659941	-0.939106	H	0.175464
C	4.273008	-1.624081	-1.921509	C	4.170374
H	4.270342	-2.593654	-1.396742	H	4.16635
O	4.978321	-1.418064	-2.900803	O	4.807261




**Figure S14.** Conformation analysis and calculation of ECD spectra of enantiomer of  $8\beta,13\beta$ -kaur-15-en-17-al.  $8\beta,13\beta$ -Kaur-15-en-17-al (5S, 8S, 9R, 10S, 13R-form) was the same as NMR calculation. The stating and optimized structures of the enantiomer, 5R, 8R, 9S, 10R, 13S-form, was following the table.




**Figure S15.** Experimental and calculated ECD spectra of **1**.




**Figure S16.**  $^1\text{H}$  NMR spectrum of **2**.




**Figure S17.**  $^{13}\text{C}$  NMR spectrum of **2**.




**Figure S18.** DEPT-135 spectrum of 2.




**Figure S19.** HSQC spectrum of **2**.




**Figure S20.** DQF-COSY spectrum of **2**.




**Figure S21.** HMBC spectrum of **2**.



**Figure S22.** NOESY spectrum of **2**.



**Figure S23.**  $^1\text{H}$  NMR spectrum of **3**.



**Figure S24.**  $^{13}\text{C}$  NMR spectrum of 3.





Figure S25. DEPT-135 spectrum of 3.



**Figure S26.** HSQC-TOCSY spectrum of **3**.







Figure S27. DQF-COSY spectrum of 3.




**Figure S28.** HMBC spectrum of 3.




**Figure S29.** NOESY spectrum of **3**.




**Figure S30.**  $^1\text{H}$  NMR spectrum of 4.



**Figure S31.**  $^{13}\text{C}$  NMR spectrum of 4.



**Figure S32.** DEPT-90 and DEPT-135 experiments of 4.



**Figure S33.** HSQC spectrum of 4.




Figure S34. DQF-COSY spectrum of 4.






Figure S35. HMBC spectrum of 4.




**Figure S36.** Superimposition of the crystal structure of 3,5-dihydroxy-2-naphthoic acid (C pink and O red) and the docked model (C green and O red) on *Plasmodium falciparum* lactate dehydrogenase crystal structure (PDB ID: 1U5A) with RMSD ~ 2.0 Å and their 2D interactions into the binding site. These models were generated using the Discovery Studio visualizer. The symbol A refers to the amino acids from *PfLDH*.

## H-bond profile




**Figure 37.** Hydrogen bond profiles obtained from MD simulations (0–100 ns) for all systems: (a) *PfLDH*-apo, (b) *PfLDH*-control, (c) *PfLDH*-1, and (d) *PfLDH*-2. The H-bond interactions between enzyme residues are represented in red, while the enzyme-ligand interactions are in black.



**Figure S38.** Specimen ID and sample report of *P. polystachyus*.

**Table S1.** Infection rates of compounds **1** and **2** in comparison to artemisinin as the reference drug.

Compound	Concentration	Average of infection rate (%)	Standard deviation	n=1	n=2	n=3
<b>1</b> [ $\mu\text{g/ml}$ ]	0.01	106	10	118	103	98
	0.03	106	5	111	100	106
	0.1	103	6	98	101	109
	0.3	108	7	116	106	102
	1	87	4	87	83	91
	3	53	8	45	60	54
	10	20	7	27	19	14
	30	14	2	17	13	13
<b>2</b> [ $\mu\text{g/ml}$ ]	0.01	107	10	118	103	99
	0.03	107	4	106	111	103
	0.1	110	9	120	102	108
	0.3	107	3	108	110	103
	1	106	4	104	110	103
	3	99	5	94	99	103
	10	62	10	54	58	73
	30	29	12	43	21	23
Artemisinin [nM]	0.1	102	5	96	105	104
	0.3	95	5	100	92	92
	1	100	5	106	96	99
	3	97	7	90	97	104
	10	65	2	68	64	64
	30	12	1	11	13	12
	100	8	1	8	8	6
	300	6	2	7	4	6



**Table S2.** IC<sub>50</sub> of compounds **1** and **2** in comparison to artemisinin as the reference drug.

Compound	Average of IC <sub>50</sub>	Standard deviation	n=1	n=2	n=3
<b>1</b> [ $\mu\text{g/ml}$ ]	3.4 (12 $\mu\text{M}$ )	0.7	2.6	4.0	3.4
<b>2</b> [ $\mu\text{g/ml}$ ]	15 (52 $\mu\text{M}$ )	2.0	15	13	17
Artemisinin [nM]	14	0.4	14	14	13